Related Experiment Video

Updated: May 13, 2026

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice
07:02

In Vivo Inhibition of MicroRNA to Decrease Tumor Growth in Mice

Published on: August 23, 2019

Association between the rs2910164 polymorphism in pre-Mir-146a sequence and thyroid carcinogenesis

Wen-Jun Wei1, Yu-Long Wang, Duan-Shu Li

  • 1Department of Head & Neck Surgery, Cancer Hospital, Fudan University, Shanghai, China.

Plos One
|March 2, 2013
PubMed
Abstract

Insights

The single nucleotide polymorphism rs2910164 in miR-146a was not linked to papillary thyroid cancer or benign thyroid tumor risk in Chinese patients. However, the GG genotype may increase the risk of benign tumors progressing to papillary thyroid cancer.

Area of Science:

  • Genetics
  • Oncology
  • Molecular Biology

Background:

  • Rs2910164, a single nucleotide polymorphism (SNP) in the precursor microRNA sequence of miR-146a, is the sole microRNA sequence SNP investigated in papillary thyroid cancer (PTC).
  • Previous association studies in US and UK-Northern European populations yielded inconsistent results regarding rs2910164 and PTC risk.
  • This study aimed to evaluate the association between rs2910164 and the risk of PTC and benign thyroid tumors (BN), and to examine clinicopathological characteristics across different genotypes.

Purpose of the Study:

  • To investigate the association between the rs2910164 polymorphism and the risk of papillary thyroid cancer (PTC) and benign thyroid tumors (BN) in a Chinese Han population.
  • To analyze the clinicopathological characteristics of PTC and BN in relation to rs2910164 genotypes.
  • To explore the potential role of rs2910164 in the progression from benign thyroid tumors to PTC.

Main Methods:

  • A case-control study involving 753 PTC cases, 484 BN cases, and 760 controls from a Chinese Han population.
  • Genotyping of the rs2910164 polymorphism.
  • Comparison of clinicopathological and genetic data using multivariate logistic regression to calculate adjusted odds ratios (ORs).

Main Results:

  • No significant differences in rs2910164 genotype distributions were observed among PTC, BN, and control groups.
  • PTC cases with co-existing benign tumors (PTC/BN) exhibited distinct characteristics, including older age, smaller tumor size, lower serum thyrotropin levels, and reduced lymph node metastasis rates compared to PTC-only cases.
  • The rs2910164 GG homozygote was identified as the sole significant risk factor (OR=2.25, P=0.01) for the progression from benign thyroid tumor to PTC.

Conclusions:

  • Rs2910164 is not associated with an increased risk of developing papillary thyroid cancer or benign thyroid tumors in the Chinese population.
  • The rs2910164 polymorphism, specifically the GG genotype, may play a role in the latent transformation of benign thyroid tumors into papillary thyroid cancer.

More Related Videos

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform06:21

Multi-Gene Single Nucleotide Polymorphism Detection in Gastric Cancer Based on Ion Semiconductor Sequencing Platform

Published on: May 10, 2024

Related Concept Videos

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA (lncRNA)...
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
Graves' Disease I: Introduction01:28

Graves' Disease I: Introduction

Graves' disease is an autoimmune disorder that causes hyperthyroidism, or overactivity of the thyroid gland. It results from autoantibodies called thyroid-stimulating immunoglobulins (TSIs), which bind to thyroid-stimulating hormone (TSH) receptors, leading to overstimulation of hormone production and a hypermetabolic state.EtiologyAlthough considered idiopathic, Graves’ disease has well-established contributing factors. There is a strong genetic component, with increased prevalence in...
Mutagenicity and Carcinogenicity01:25

Mutagenicity and Carcinogenicity

Mutagenicity and carcinogenicity refer to the ability of drugs to cause genetic defects and induce cancer, respectively. The International Agency for Research on Cancer (IARC) classifies agents into four groups based on their carcinogenic potential. Group 1 agents are known human carcinogens; group 2A agents are probably carcinogenic to humans; group 3 agents lack data to support their role in carcinogenesis; and group 4 includes agents for which data support that they are not likely to be...
MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns—non-coding regions of a gene—or intergenic regions—stretches of DNA present between genes. Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA ends...